Company Overview

Jubilant Pharmova Limited (BSE: 530019, NSE: JUBLPHARMA) has released comprehensive FY26 disclosures including financial results, corporate governance report, and notice for its 48th Annual General Meeting scheduled for August 26, 2026.

Financial Performance Highlights

FY26 consolidated financial results showed strong performance with revenue from operations growing 14% to ₹82,796 million and normalized PAT increasing 7% to ₹4,424 million. The company reported net profit of ₹3,975 million with EBITDA of ₹13,255 million (8% growth), though EBITDA margin decreased 99 bps to 15.9%. Key segments performed well: Radiopharma (₹36,901 million, 9% growth), CDMO Sterile Injectables (₹17,548 million, 38% growth), and Allergy Immunotherapy (₹7,853 million, 12% growth).

Corporate Actions and Significant Events

The Board has recommended a final dividend of ₹5 per equity share (500%) subject to approval at the upcoming AGM, with record date set for July 24, 2026. The company completed the slump sale of its API business to wholly-owned subsidiary Jubilant Biosys Limited for ₹5,956 million consideration (₹800 million cash + ₹5,156 million preference shares), completed on September 1, 2025. The Group recognized an impairment of ₹87 million on its investment in associate SPV Laboratories Private Limited and capitalized significant expenditure including ₹11,713 million for a new manufacturing facility by Jubilant HollisterStier LLC.

Corporate Governance and Compliance

All four Board committees met regularly with excellent attendance records - the Nomination and Remuneration Committee held 4 meetings with 100% attendance, while 12 investor complaints were resolved satisfactorily. Executive Directors received ₹74.96 million in remuneration while Non-Executive Directors earned ₹23 million in fees and commissions. The company maintains comprehensive policies including Code of Conduct, Insider Trading prevention, and Whistle Blower mechanisms, with auditors confirming strong internal financial controls.

AGM Details and Shareholder Information

The 48th AGM will be held on August 26, 2026 via video conferencing, with business including adoption of financial statements, dividend declaration, and re-appointment of directors Hari S. Bhartia and Arjun Shanker Bhartia. E-voting will be available from August 23-25, 2026 through NSDL platform. The company has 99.79% dematerialized shareholding with 61,259 shares transferred to IEPF Authority due to unclaimed dividends.

Regulatory and Macro Considerations

The Group assessed the impact of newly notified Indian Labour Codes, recognizing an incremental provision of ₹133 million primarily for gratuity and compensated absences. Auditors highlighted key audit matters including impairment testing of ₹28.3 billion goodwill, revenue recognition across diverse pharmaceutical segments, and capital expenditure validation. Contingent liabilities include disputed tax claims of ₹3,681 million and various other regulatory matters.

Forward Outlook and Strategic Initiatives

The company continues progress toward Vision 2030 targets including doubling revenues from FY24 levels, achieving 23-25% EBITDA margins, zero net debt, and high teens ROCE. ESG performance remains strong with NSE Sustainability score of 72/100 ('Leader' category) and certifications as Great Place to Work® in both India and US operations.